PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells.
CD4+
CD8+
PD-L1
melanoma tumor microenvironment cells
tumor-infiltrating lymphocytes
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
27 Jan 2023
27 Jan 2023
Historique:
received:
20
12
2022
revised:
21
01
2023
accepted:
25
01
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
(1) Background: Because melanoma is an aggressive tumor with an unfavorable prognosis, we aimed to characterize the PD-L1 expression in melanomas in association with T cell infiltrates because PD-1/PD-L1 blockade represents the target in treating melanoma strategy. (2) Methods: The immunohistochemical manual quantitative methods of PD-L1, CD4, and CD8 TILs were performed in melanoma tumor microenvironment cells. (3) Results: Most of the PD-L1 positive, expressing tumors, have a moderate score of CD4+ TILs and CD8+TILs (5-50% of tumor area) in tumoral melanoma environment cells. The PD-L1 expression in TILs was correlated with different degrees of lymphocytic infiltration described by the Clark system (X
Identifiants
pubmed: 36836455
pii: jpm13020221
doi: 10.3390/jpm13020221
pmc: PMC9965691
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ovidius University from Constanta, Romania
ID : 06/November 14th, 2018
Références
Cancer Cell. 2015 Apr 13;27(4):450-61
pubmed: 25858804
Medicine (Baltimore). 2018 Oct;97(43):e12858
pubmed: 30412078
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Histopathology. 2018 Sep;73(3):386-396
pubmed: 29637587
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Int J Biol Markers. 2017 Mar 2;32(1):e68-e74
pubmed: 27470134
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Clin Cancer Res. 2017 Aug 1;23(15):4270-4279
pubmed: 28223273
Pigment Cell Melanoma Res. 2015 May;28(3):245-53
pubmed: 25477049
Clin Cancer Res. 2018 Nov 1;24(21):5250-5260
pubmed: 30021908
Curr Protein Pept Sci. 2019;20(1):82-91
pubmed: 30264678
Melanoma Res. 2020 Feb;30(1):85-101
pubmed: 31095042
Oncoimmunology. 2016 Feb 18;5(5):e1143997
pubmed: 27467964
Cancer. 2011 May 15;117(10):2192-201
pubmed: 21523733
Rom J Morphol Embryol. 2009;50(4):701-5
pubmed: 19942969
Cancer Res. 2016 Dec 1;76(23):6964-6974
pubmed: 27671674
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Eur J Cancer. 2018 Jan;88:67-76
pubmed: 29195116
Clin Cancer Res. 2016 Aug 1;22(15):3915-23
pubmed: 26960397
Histopathology. 2018 May;72(6):1024-1032
pubmed: 29323731
Blood. 2009 Aug 20;114(8):1537-44
pubmed: 19423728
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
Lancet. 2014 Sep 20;384(9948):1109-17
pubmed: 25034862
Cancer Cell Int. 2019 May 23;19:146
pubmed: 31143091
Mod Pathol. 2016 Nov;29(11):1433-1442
pubmed: 27443512
Cancers (Basel). 2019 Sep 11;11(9):
pubmed: 31514399
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Oncologist. 2020 Feb;25(2):e291-e301
pubmed: 32043781
Onco Targets Ther. 2016 May 04;9:2649-54
pubmed: 27226727
Cancer. 2001 Feb 15;91(4):874-80
pubmed: 11241258
J Thorac Oncol. 2016 Jul;11(7):964-75
pubmed: 27117833
Neoplasia. 2006 Mar;8(3):190-8
pubmed: 16611412
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Clin Cancer Res. 2019 Sep 1;25(17):5191-5201
pubmed: 30923036
Melanoma Res. 2015 Apr;25(2):113-8
pubmed: 25602697
Clin Cancer Res. 2014 May 15;20(10):2773-82
pubmed: 24647569
Oncoimmunology. 2018 Sep 5;7(12):e1405206
pubmed: 30524879
BMC Urol. 2017 Jan 13;17(1):8
pubmed: 28086852
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
J Cell Physiol. 2019 Feb;234(2):1313-1325
pubmed: 30191996
Clin Cancer Res. 2016 Apr 15;22(8):1969-77
pubmed: 26573597
Ann Oncol. 2016 Mar;27(3):409-16
pubmed: 26681673
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Cells. 2021 Sep 29;10(10):
pubmed: 34685565
Diagn Pathol. 2018 Jan 17;13(1):5
pubmed: 29378617
Cancer Biol Med. 2018 Aug;15(3):290-298
pubmed: 30197796
Melanoma Manag. 2016 Sep;3(3):187-194
pubmed: 30190888
Cancer Biol Ther. 2019;20(6):941-947
pubmed: 30866717
Lab Invest. 2017 Sep;97(9):1063-1071
pubmed: 28737763
Cancer Cell Int. 2020 Mar 30;20:96
pubmed: 32256205
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Medicine (Baltimore). 2019 Nov;98(47):e18122
pubmed: 31764853
J Surg Oncol. 2019 Oct;120(5):873-881
pubmed: 31246291
Invest New Drugs. 2016 Dec;34(6):677-684
pubmed: 27491654
Clin Cancer Res. 2017 Oct 15;23(20):6054-6061
pubmed: 28724663
Target Oncol. 2016 Apr;11(2):143-8
pubmed: 26429561
Ann Dermatol. 2013 Feb;25(1):61-6
pubmed: 23467045
Lab Invest. 2014 Jan;94(1):107-16
pubmed: 24217091
J Cancer. 2014 Jan 24;5(3):166-72
pubmed: 24563671
Biomedicines. 2022 Jul 12;10(7):
pubmed: 35884977
Cancer. 2010 Apr 1;116(7):1757-66
pubmed: 20143437
Melanoma Res. 2015 Dec;25(6):503-9
pubmed: 26352784
Mol Cancer Ther. 2011 Aug;10(8):1520-8
pubmed: 21659462
J Immunother Cancer. 2018 May 9;6(1):32
pubmed: 29743104
Histopathology. 2015 Oct;67(4):548-56
pubmed: 25809697
Oncoimmunology. 2016 Sep 20;5(11):e1235107
pubmed: 27999753
Cancer Sci. 2019 Feb;110(2):489-498
pubmed: 30548363
Ann Oncol. 2014 Dec;25(12):2433-2442
pubmed: 25223485
Ann Oncol. 2015 Sep;26(9):1980-1987
pubmed: 26037795
Cancer Immunol Res. 2015 Feb;3(2):110-5
pubmed: 25370533
Int J Cancer. 2012 May 15;130(10):2327-36
pubmed: 21717461
Mol Cancer. 2019 Jan 15;18(1):10
pubmed: 30646912
Clin Cancer Res. 2017 Aug 15;23(16):4938-4944
pubmed: 28428193
Medicine (Baltimore). 2021 May 21;100(20):e25944
pubmed: 34011073